Pfizer (PFE) Share-based Compensation (2009 - 2026)

Pfizer (PFE) has 18 years of Share-based Compensation data on file, last reported at $272.0 million in Q1 2026.

• Quarterly Share-based Compensation rose 60.0% year-over-year to $272.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $901.0 million (down 30.48% YoY) and the FY2025 annual result came in at $799.0 million, down 8.89% from the prior year.
• Share-based Compensation climbed to $272.0 million in Q1 2026 per PFE's latest filing, from $225.0 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $700.0 million in Q3 2024 and bottomed at $86.0 million in Q2 2022.
• The 5-year median for Share-based Compensation is $203.0 million (2025), against an average of $240.2 million.
• The widest annual swing landed in 2024, when Share-based Compensation jumped 363.58%; it then plunged 71.29% in 2025.
• Tracing PFE's Share-based Compensation over 5 years: stood at $508.0 million in 2022, then tumbled by 76.18% to $121.0 million in 2023, then soared by 478.51% to $700.0 million in 2024, then sank by 67.86% to $225.0 million in 2025, then grew by 20.89% to $272.0 million in 2026.
• Per Business Quant, the three latest PFE Share-based Compensation figures stand at $272.0 million (Q1 2026), $225.0 million (Q4 2025), and $201.0 million (Q3 2025).

Peer Comparison